Crinetics Pharmaceuticals, Inc. is a biotech company developing new medicines.
Crinetics Pharmaceuticals, Inc. (CRNX) is expected to report earnings on Thursday, November 5, 2026, after the close. Estimated release time 16:15 ET. Consensus EPS estimate is $-1.20.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-03 | FY2026 Q2 | $-1.18 | $-1.14 | +3.4% | $25.12M |
| 2026-05-07 | FY2026 Q1 | $-1.22 | $-1.23 | -0.8% | $10.73M |
| 2026-02-26 | FY2025 Q4 | $-1.37 | $-1.30 | +5.1% | $6.16M |
| 2025-08-07 | FY2025 Q2 | $-1.13 | $-1.23 | -8.8% | $1.03M |
| 2025-05-08 | FY2025 Q1 | $-0.99 | $-1.04 | -5.1% | $361.00K |
| 2024-08-08 | FY2024 Q2 | $-0.86 | $-0.94 | -9.3% | $399.00K |
| 2024-05-09 | FY2024 Q1 | $-0.84 | $-0.93 | -10.7% | $640.00K |
| 2023-12-31 | FY2023 Q4 | — | $-0.89 | — | $0 |
CRNX has beaten consensus EPS in 2 of its last 8 reported quarters.
Highlights from CRNX's Aug 3 report: EPS of -$1.14 — a beat vs the -$1.18 estimate (+3%); revenue of $25M — a big beat vs the $15M consensus (+69%).
See CRNX on the live calendar →